HRP20160635T1 - Inhibitori pirimidina pde10 - Google Patents
Inhibitori pirimidina pde10 Download PDFInfo
- Publication number
- HRP20160635T1 HRP20160635T1 HRP20160635TT HRP20160635T HRP20160635T1 HR P20160635 T1 HRP20160635 T1 HR P20160635T1 HR P20160635T T HRP20160635T T HR P20160635TT HR P20160635 T HRP20160635 T HR P20160635T HR P20160635 T1 HRP20160635 T1 HR P20160635T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- methoxy
- pyrimidin
- cyclopropyl
- amine
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 (1) pyridyl Chemical group 0.000 claims 97
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 67
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 65
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 50
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 14
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- VGQVCSXKCPHNPV-UHFFFAOYSA-N 6-[[2-(6,7-dihydro-5h-cyclopenta[b]pyridin-2-yl)cyclopropyl]methoxy]-5-fluoro-4-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OCC2C(C2)C=2N=C3CCCC3=CC=2)=C1F VGQVCSXKCPHNPV-UHFFFAOYSA-N 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- YETFMBYLZZBYOX-OLZOCXBDSA-N 2-amino-4-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidine-5-carbonitrile Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=C1C#N YETFMBYLZZBYOX-OLZOCXBDSA-N 0.000 claims 3
- XOOGTCKSDYCAQG-UHFFFAOYSA-N 2-ethyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(CC)=NC=1NCC=1C=NN(C)C=1 XOOGTCKSDYCAQG-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- SVCNXXHZQUMJNJ-UCWKZMIHSA-N 1-[5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazol-2-yl]ethanol Chemical compound S1C(C(O)C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 SVCNXXHZQUMJNJ-UCWKZMIHSA-N 0.000 claims 2
- WQKPZDLZRFTMTI-CABCVRRESA-N 2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 WQKPZDLZRFTMTI-CABCVRRESA-N 0.000 claims 2
- LWZXBBCMVOLFBF-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 LWZXBBCMVOLFBF-UHFFFAOYSA-N 0.000 claims 2
- CRAJFQTZUQEAOM-UHFFFAOYSA-N 2-methyl-n-[(2-methyl-1,3-thiazol-5-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=N1 CRAJFQTZUQEAOM-UHFFFAOYSA-N 0.000 claims 2
- XGWSTNMIYQJSDN-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,2-oxazol-3-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound O1C(C)=CC(CNC=2N=C(C)N=C(OCC3C(C3)C=3N=CC=CC=3)C=2)=N1 XGWSTNMIYQJSDN-UHFFFAOYSA-N 0.000 claims 2
- CCHBPYICGBRMKE-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=N1 CCHBPYICGBRMKE-UHFFFAOYSA-N 0.000 claims 2
- PIRMCOIXKTYSAA-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(5-pyridin-3-ylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2C=NC=CC=2)=NC(C)=N1 PIRMCOIXKTYSAA-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 2
- XHXPIUHBETTYNG-UHFFFAOYSA-N n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-fluoro-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC(C)=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC=CC=2)=C1F XHXPIUHBETTYNG-UHFFFAOYSA-N 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HJGBFEVSOPIIFN-LSDHHAIUSA-N 1-[4-[[(1r,2r)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidin-2-yl]ethanone Chemical compound C=1C(OC[C@H]2[C@@H](C2)C=2N=CC(C)=CC=2)=NC(C(=O)C)=NC=1NCC1=NN=C(C)S1 HJGBFEVSOPIIFN-LSDHHAIUSA-N 0.000 claims 1
- GEZVEUDFWZBTFE-CABCVRRESA-N 1-[5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazol-2-yl]ethanone Chemical compound S1C(C(=O)C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 GEZVEUDFWZBTFE-CABCVRRESA-N 0.000 claims 1
- SQBFBFNYKLAFJJ-UHFFFAOYSA-N 2,5-dimethyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound CC=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 SQBFBFNYKLAFJJ-UHFFFAOYSA-N 0.000 claims 1
- GAHBYCAKOYTKMH-UHFFFAOYSA-N 2-(fluoromethyl)-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(CF)=N1 GAHBYCAKOYTKMH-UHFFFAOYSA-N 0.000 claims 1
- ZKCWYUVVOBLCOJ-LSDHHAIUSA-N 2-[4-[[(1r,2r)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidin-2-yl]propan-2-ol Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@H]2[C@@H](C2)C=2N=CC(C)=CC=2)=NC(C(C)(C)O)=N1 ZKCWYUVVOBLCOJ-LSDHHAIUSA-N 0.000 claims 1
- HNXZOAHAXAGMGB-CABCVRRESA-N 2-[5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazol-2-yl]propan-2-ol Chemical compound N1=CC(C)=CC=C1[C@@H]1[C@@H](COC=2N=C(C)N=C(NCC=3SC(=NN=3)C(C)(C)O)C=2)C1 HNXZOAHAXAGMGB-CABCVRRESA-N 0.000 claims 1
- CHEVQFYKOAAXPK-ZBFHGGJFSA-N 2-[6-[(1s,2s)-2-[[2-methyl-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidin-4-yl]oxymethyl]cyclopropyl]pyridin-3-yl]propan-2-ol Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(=CC=2)C(C)(C)O)=NC(C)=N1 CHEVQFYKOAAXPK-ZBFHGGJFSA-N 0.000 claims 1
- BHHJQJCJMWJDQJ-YPMHNXCESA-N 2-amino-4-[[(1s,2s)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidine-5-carbonitrile Chemical compound N1=CC(OC)=CC=C1[C@@H]1[C@@H](COC=2C(=C(NCC=3SC(C)=NN=3)N=C(N)N=2)C#N)C1 BHHJQJCJMWJDQJ-YPMHNXCESA-N 0.000 claims 1
- DGTJMCVUCUMTLC-OLZOCXBDSA-N 2-chloro-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(Cl)=N1 DGTJMCVUCUMTLC-OLZOCXBDSA-N 0.000 claims 1
- BXNAVHOFHJKFSU-UHFFFAOYSA-N 2-cyclopropyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C1=NN(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C2CC2)=N1 BXNAVHOFHJKFSU-UHFFFAOYSA-N 0.000 claims 1
- VTGYQFHHSHAOSE-CABCVRRESA-N 2-ethyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound C=1C(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(CC)=NC=1NCC1=NN=C(C)S1 VTGYQFHHSHAOSE-CABCVRRESA-N 0.000 claims 1
- NQYKRBGQYGJWAW-UHFFFAOYSA-N 2-methoxy-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(OC)=NC=1NCC=1C=NN(C)C=1 NQYKRBGQYGJWAW-UHFFFAOYSA-N 0.000 claims 1
- XJEWSFUBWNCONC-UHFFFAOYSA-N 2-methyl-4-[(1-methylpyrazol-4-yl)methylamino]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidine-5-carbonitrile Chemical compound N#CC=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 XJEWSFUBWNCONC-UHFFFAOYSA-N 0.000 claims 1
- BXSRXGCDVBDJBS-UHFFFAOYSA-N 2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]-n-(pyridin-3-ylmethyl)pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC1=CC=CN=C1 BXSRXGCDVBDJBS-UHFFFAOYSA-N 0.000 claims 1
- MKDVDIMOSORYRP-UHFFFAOYSA-N 2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]-n-(pyridin-4-ylmethyl)pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC1=CC=NC=C1 MKDVDIMOSORYRP-UHFFFAOYSA-N 0.000 claims 1
- VOIGYMJJJONFBG-UHFFFAOYSA-N 2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]-n-(pyrimidin-5-ylmethyl)pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC1=CN=CN=C1 VOIGYMJJJONFBG-UHFFFAOYSA-N 0.000 claims 1
- WQKPZDLZRFTMTI-LSDHHAIUSA-N 2-methyl-6-[[(1r,2r)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@H]2[C@@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 WQKPZDLZRFTMTI-LSDHHAIUSA-N 0.000 claims 1
- IBPDRPBCVGELSR-CABCVRRESA-N 2-methyl-6-[[(1s,2s)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound C([C@H]1C[C@@H]1C1=NN2C=C(N=C2C=C1)C)OC(N=C(C)N=1)=CC=1NCC1=NN=C(C)S1 IBPDRPBCVGELSR-CABCVRRESA-N 0.000 claims 1
- LQTJCLWWJYOFRA-NKWVPACGSA-N 2-methyl-6-[[(1s,3s)-2-[(2-methylpropan-2-yl)oxy]-3-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2OC(C)(C)C)C=2N=CC(C)=CC=2)=NC(C)=N1 LQTJCLWWJYOFRA-NKWVPACGSA-N 0.000 claims 1
- XQFXSUUXRFZHGR-UHFFFAOYSA-N 2-methyl-6-[[2-(1-methylpyrazol-3-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C2=NN(C)C=C2)=NC(C)=N1 XQFXSUUXRFZHGR-UHFFFAOYSA-N 0.000 claims 1
- IBPDRPBCVGELSR-UHFFFAOYSA-N 2-methyl-6-[[2-(2-methylimidazo[1,2-b]pyridazin-6-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound C1=CC2=NC(C)=CN2N=C1C1CC1COC(N=C(C)N=1)=CC=1NCC1=NN=C(C)S1 IBPDRPBCVGELSR-UHFFFAOYSA-N 0.000 claims 1
- NUDRSTWQGCJJFH-UHFFFAOYSA-N 2-methyl-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NC=C1CNC1=CC(OCC2C(C2)C=2N=CC(C)=CC=2)=NC(C)=N1 NUDRSTWQGCJJFH-UHFFFAOYSA-N 0.000 claims 1
- OZNYHXLBMZWKJB-UHFFFAOYSA-N 2-methyl-6-[[2-(6-methylpyridazin-3-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=NC(C)=CC=2)=NC(C)=N1 OZNYHXLBMZWKJB-UHFFFAOYSA-N 0.000 claims 1
- VDONBDAZPNHPQM-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=C3C=CC=CC3=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 VDONBDAZPNHPQM-UHFFFAOYSA-N 0.000 claims 1
- LHBVYTOIFVBQNY-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[[2-(1,3-thiazol-4-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CSC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 LHBVYTOIFVBQNY-UHFFFAOYSA-N 0.000 claims 1
- ZSFFDBSICCJUJN-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=C3C=CC=NC3=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 ZSFFDBSICCJUJN-UHFFFAOYSA-N 0.000 claims 1
- VRMWBFAABMFGGZ-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1C1C(COC=2N=C(C)N=C(NCC3=CN(C)N=C3)C=2)C1 VRMWBFAABMFGGZ-UHFFFAOYSA-N 0.000 claims 1
- QKJVVLGZBJCDTG-UHFFFAOYSA-N 2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[[2-[5-(trifluoromethyl)pyridin-2-yl]cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC(=CC=2)C(F)(F)F)=NC(C)=NC=1NCC=1C=NN(C)C=1 QKJVVLGZBJCDTG-UHFFFAOYSA-N 0.000 claims 1
- ANYKNJFUWXWROF-UHFFFAOYSA-N 2-methyl-n-[(2-methyl-1,3-thiazol-5-yl)methyl]-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=CC3=CC=2)=NC(C)=N1 ANYKNJFUWXWROF-UHFFFAOYSA-N 0.000 claims 1
- PCINJCMXJVAFDP-UHFFFAOYSA-N 2-methyl-n-[(3-methylpyridin-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC1=CC=NC=C1C PCINJCMXJVAFDP-UHFFFAOYSA-N 0.000 claims 1
- PGGVSTRAIQRNSK-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyrazolo[1,5-a]pyrimidin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C2=NN3C=CC=NC3=C2)=NC(C)=N1 PGGVSTRAIQRNSK-UHFFFAOYSA-N 0.000 claims 1
- FOXLJPYUMZWSHZ-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyrazolo[1,5-a]pyrimidin-5-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C2=NC3=CC=NN3C=C2)=NC(C)=N1 FOXLJPYUMZWSHZ-UHFFFAOYSA-N 0.000 claims 1
- YBMJDDULNBKSSL-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=CC3=CC=2)=NC(C)=N1 YBMJDDULNBKSSL-UHFFFAOYSA-N 0.000 claims 1
- PGGVSTRAIQRNSK-KGLIPLIRSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[(1s,2s)-2-pyrazolo[1,5-a]pyrimidin-2-ylcyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C2=NN3C=CC=NC3=C2)=NC(C)=N1 PGGVSTRAIQRNSK-KGLIPLIRSA-N 0.000 claims 1
- YWPPZQMTZSRPCK-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=NC3=CC=2)=NC(C)=N1 YWPPZQMTZSRPCK-UHFFFAOYSA-N 0.000 claims 1
- JYSZEFHAXOTAIN-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(5-pyrazol-1-ylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)N2N=CC=C2)=NC(C)=N1 JYSZEFHAXOTAIN-UHFFFAOYSA-N 0.000 claims 1
- ONZTXYRQLKNVNV-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(5-pyridazin-4-ylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2C=NN=CC=2)=NC(C)=N1 ONZTXYRQLKNVNV-UHFFFAOYSA-N 0.000 claims 1
- YVSMZUKCUAZKRF-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(5-pyridin-2-ylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2N=CC=CC=2)=NC(C)=N1 YVSMZUKCUAZKRF-UHFFFAOYSA-N 0.000 claims 1
- DVEAUHLGRZWUSA-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(5-pyridin-4-ylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2C=CN=CC=2)=NC(C)=N1 DVEAUHLGRZWUSA-UHFFFAOYSA-N 0.000 claims 1
- OYLPIGAXOISTQL-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-[5-(1,3-thiazol-2-yl)pyridin-2-yl]cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2SC=CN=2)=NC(C)=N1 OYLPIGAXOISTQL-UHFFFAOYSA-N 0.000 claims 1
- YTOUAKABUWKZMB-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-[5-(1,3-thiazol-4-yl)pyridin-2-yl]cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2N=CSC=2)=NC(C)=N1 YTOUAKABUWKZMB-UHFFFAOYSA-N 0.000 claims 1
- SMHRKJHCTZIZCJ-UHFFFAOYSA-N 2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-[5-(1,3-thiazol-5-yl)pyridin-2-yl]cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C=2SC=NC=2)=NC(C)=N1 SMHRKJHCTZIZCJ-UHFFFAOYSA-N 0.000 claims 1
- SCIOOVBAMBHQGV-UHFFFAOYSA-N 2-methyl-n-[(5-methylpyrazin-2-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C1=NC(C)=CN=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=N1 SCIOOVBAMBHQGV-UHFFFAOYSA-N 0.000 claims 1
- ULHWDTRMWCSILP-UHFFFAOYSA-N 4-[(1-methylpyrazol-4-yl)methylamino]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidine-2-carbonitrile Chemical compound C1=NN(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C#N)=N1 ULHWDTRMWCSILP-UHFFFAOYSA-N 0.000 claims 1
- VNWZUPSPHKSFAM-UHFFFAOYSA-N 4-[(1-methylpyrazol-4-yl)methylamino]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidine-2-carboxamide Chemical compound C1=NN(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C(N)=O)=N1 VNWZUPSPHKSFAM-UHFFFAOYSA-N 0.000 claims 1
- RLRNPDPIFQFWCW-UHFFFAOYSA-N 4-[(2,4-dimethyl-1,3-thiazol-5-yl)methylamino]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidine-5-carbonitrile Chemical compound S1C(C)=NC(C)=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC=CC=2)=C1C#N RLRNPDPIFQFWCW-UHFFFAOYSA-N 0.000 claims 1
- WDYPTUUBBAWXGM-QWHCGFSZSA-N 4-[[(1r,2r)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidine-2-carboxylic acid Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@H]2[C@@H](C2)C=2N=CC(C)=CC=2)=NC(C(O)=O)=N1 WDYPTUUBBAWXGM-QWHCGFSZSA-N 0.000 claims 1
- BJJUVLGFVIPMKT-KGLIPLIRSA-N 5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazole-2-carbonitrile Chemical compound N1=CC(C)=CC=C1[C@@H]1[C@@H](COC=2N=C(C)N=C(NCC=3SC(=NN=3)C#N)C=2)C1 BJJUVLGFVIPMKT-KGLIPLIRSA-N 0.000 claims 1
- QPFYNVGHLBATNA-OLZOCXBDSA-N 5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazole-2-carboxamide Chemical compound N1=CC(C)=CC=C1[C@@H]1[C@@H](COC=2N=C(C)N=C(NCC=3SC(=NN=3)C(N)=O)C=2)C1 QPFYNVGHLBATNA-OLZOCXBDSA-N 0.000 claims 1
- QRQRHXHVRZZAGE-UHFFFAOYSA-N 5-bromo-n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC(C)=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC=CC=2)=C1Br QRQRHXHVRZZAGE-UHFFFAOYSA-N 0.000 claims 1
- QDKKCDOWLNRECK-UHFFFAOYSA-N 5-chloro-2-methyl-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC(C)=CC=2)=C1Cl QDKKCDOWLNRECK-UHFFFAOYSA-N 0.000 claims 1
- YLEJCSHLOMHMLB-NEPJUHHUSA-N 5-chloro-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-2-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=C(Cl)C(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=N1 YLEJCSHLOMHMLB-NEPJUHHUSA-N 0.000 claims 1
- YLEJCSHLOMHMLB-UHFFFAOYSA-N 5-chloro-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-2-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=C(Cl)C(OCC2C(C2)C=2N=CC(C)=CC=2)=N1 YLEJCSHLOMHMLB-UHFFFAOYSA-N 0.000 claims 1
- YNJFHYRVZWTWRW-UHFFFAOYSA-N 5-fluoro-2-methyl-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC(C)=CC=2)=C1F YNJFHYRVZWTWRW-UHFFFAOYSA-N 0.000 claims 1
- VQWYNNHCUBTALG-UHFFFAOYSA-N 5-fluoro-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound FC=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 VQWYNNHCUBTALG-UHFFFAOYSA-N 0.000 claims 1
- DJIHGFGILNHBKU-NEPJUHHUSA-N 5-fluoro-6-[[(1s,2s)-2-(6-methylpyridin-2-yl)cyclopropyl]methoxy]-4-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OC[C@@H]2[C@H](C2)C=2N=C(C)C=CC=2)=C1F DJIHGFGILNHBKU-NEPJUHHUSA-N 0.000 claims 1
- DJIHGFGILNHBKU-UHFFFAOYSA-N 5-fluoro-6-[[2-(6-methylpyridin-2-yl)cyclopropyl]methoxy]-4-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OCC2C(C2)C=2N=C(C)C=CC=2)=C1F DJIHGFGILNHBKU-UHFFFAOYSA-N 0.000 claims 1
- ZBCQOCIXCUHNFS-UHFFFAOYSA-N 6-[2-[[2-methyl-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidin-4-yl]oxymethyl]cyclopropyl]pyridine-3-carbonitrile Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C#N)=NC(C)=N1 ZBCQOCIXCUHNFS-UHFFFAOYSA-N 0.000 claims 1
- YYLSSHGCJRBQCZ-KGLIPLIRSA-N 6-[[(1s,2s)-2-(4,5-dimethylpyridin-2-yl)cyclopropyl]methoxy]-2-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=C(C)C=2)=N1 YYLSSHGCJRBQCZ-KGLIPLIRSA-N 0.000 claims 1
- OCEMWRITCMJZIX-HIFRSBDPSA-N 6-[[(1s,2s)-2-(5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C2=NN3CCCC3=C2)=NC(C)=N1 OCEMWRITCMJZIX-HIFRSBDPSA-N 0.000 claims 1
- YBFMFDLTLQYBEY-PWSUYJOCSA-N 6-[[(1s,2s)-2-(5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-yl)cyclopropyl]methoxy]-5-fluoro-4-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OC[C@@H]2[C@H](C2)C2=NN3CCCC3=C2)=C1F YBFMFDLTLQYBEY-PWSUYJOCSA-N 0.000 claims 1
- JYOKKXWVFCGTBY-UHFFFAOYSA-N 6-[[2-(3-methoxypyridin-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-amine Chemical compound COC1=CC=CN=C1C1C(COC=2N=C(C)N=C(NCC3=CN(C)N=C3)C=2)C1 JYOKKXWVFCGTBY-UHFFFAOYSA-N 0.000 claims 1
- YYLSSHGCJRBQCZ-UHFFFAOYSA-N 6-[[2-(4,5-dimethylpyridin-2-yl)cyclopropyl]methoxy]-2-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=CC(OCC2C(C2)C=2N=CC(C)=C(C)C=2)=N1 YYLSSHGCJRBQCZ-UHFFFAOYSA-N 0.000 claims 1
- OCEMWRITCMJZIX-UHFFFAOYSA-N 6-[[2-(5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C2=NN3CCCC3=C2)=NC(C)=N1 OCEMWRITCMJZIX-UHFFFAOYSA-N 0.000 claims 1
- YBFMFDLTLQYBEY-UHFFFAOYSA-N 6-[[2-(5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-yl)cyclopropyl]methoxy]-5-fluoro-4-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine Chemical compound S1C(C)=NN=C1CNC1=NC(N)=NC(OCC2C(C2)C2=NN3CCCC3=C2)=C1F YBFMFDLTLQYBEY-UHFFFAOYSA-N 0.000 claims 1
- YXYPFAJTRWPTLI-UHFFFAOYSA-N 6-[[2-(5-cyclopropylpyridin-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C2CC2)=NC(C)=N1 YXYPFAJTRWPTLI-UHFFFAOYSA-N 0.000 claims 1
- MOWJHNCYLAKNEL-UHFFFAOYSA-N 6-[[2-(5-fluoropyridin-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC(F)=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 MOWJHNCYLAKNEL-UHFFFAOYSA-N 0.000 claims 1
- CDGPBCFXEZRSGN-UHFFFAOYSA-N 6-[[2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-amine Chemical compound N1=CC(OC)=CC=C1C1C(COC=2N=C(C)N=C(NCC3=CN(C)N=C3)C=2)C1 CDGPBCFXEZRSGN-UHFFFAOYSA-N 0.000 claims 1
- HWGYQKJJKCFLIX-UHFFFAOYSA-N 6-[[2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-2-methyl-n-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrimidin-4-amine Chemical compound N1=CC(OC)=CC=C1C1C(COC=2N=C(C)N=C(NCC=3SC(C)=NC=3)C=2)C1 HWGYQKJJKCFLIX-UHFFFAOYSA-N 0.000 claims 1
- LCXTTZGDWBFLMV-UHFFFAOYSA-N 6-[[2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound N1=CC(OC)=CC=C1C1C(COC=2N=CN=C(NCC=3SC(C)=NN=3)C=2)C1 LCXTTZGDWBFLMV-UHFFFAOYSA-N 0.000 claims 1
- CJHDLQFJAFARQO-UHFFFAOYSA-N 6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2-(trifluoromethyl)pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(C)=CC=2)=NC(C(F)(F)F)=N1 CJHDLQFJAFARQO-UHFFFAOYSA-N 0.000 claims 1
- REHMRTWFHQPWDT-UHFFFAOYSA-N 6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(C)=CC=2)=NC=N1 REHMRTWFHQPWDT-UHFFFAOYSA-N 0.000 claims 1
- SGMUVWJQJPJTOI-UHFFFAOYSA-N 6-[[2-[5-(difluoromethyl)pyridin-2-yl]cyclopropyl]methoxy]-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC(=CC=2)C(F)F)=NC(C)=NC=1NCC=1C=NN(C)C=1 SGMUVWJQJPJTOI-UHFFFAOYSA-N 0.000 claims 1
- DDXASWALQFQUHI-UHFFFAOYSA-N 6-[[2-[5-(difluoromethyl)pyridin-2-yl]cyclopropyl]methoxy]-2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(=CC=2)C(F)F)=NC(C)=N1 DDXASWALQFQUHI-UHFFFAOYSA-N 0.000 claims 1
- OALZXROIMCDZLX-UHFFFAOYSA-N 6-[[2-[5-(fluoromethyl)pyridin-2-yl]cyclopropyl]methoxy]-2-methyl-n-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC(CF)=CC=2)=NC(C)=NC=1NCC=1C=NN(C)C=1 OALZXROIMCDZLX-UHFFFAOYSA-N 0.000 claims 1
- IOPRAYREBMIXCF-UHFFFAOYSA-N 6-[[2-[5-(fluoromethyl)pyridin-2-yl]cyclopropyl]methoxy]-2-methyl-n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC(CF)=CC=2)=NC(C)=N1 IOPRAYREBMIXCF-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- CWEMEUXBLCEFAH-LSDHHAIUSA-N ethyl 4-[[(1r,2r)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-6-[(5-methyl-1,3,4-thiadiazol-2-yl)methylamino]pyrimidine-2-carboxylate Chemical compound C=1C(OC[C@H]2[C@@H](C2)C=2N=CC(C)=CC=2)=NC(C(=O)OCC)=NC=1NCC1=NN=C(C)S1 CWEMEUXBLCEFAH-LSDHHAIUSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- QBWFNYUPMJUHMQ-KGLIPLIRSA-N methyl 5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazole-2-carboxylate Chemical compound S1C(C(=O)OC)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 QBWFNYUPMJUHMQ-KGLIPLIRSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- BZRZEZKMLNXMSS-UHFFFAOYSA-N n-[(1-methylpyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]-2-(trifluoromethyl)pyrimidin-4-amine Chemical compound C1=NN(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C(F)(F)F)=N1 BZRZEZKMLNXMSS-UHFFFAOYSA-N 0.000 claims 1
- SJCKAGOBSNUNNF-UHFFFAOYSA-N n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-2,5-dimethyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC(C)=C1CNC1=NC(C)=NC(OCC2C(C2)C=2N=CC=CC=2)=C1C SJCKAGOBSNUNNF-UHFFFAOYSA-N 0.000 claims 1
- ORIHNIXARSTBJH-UHFFFAOYSA-N n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-2-ethyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(CC)=NC=1NCC=1SC(C)=NC=1C ORIHNIXARSTBJH-UHFFFAOYSA-N 0.000 claims 1
- GHKQPVUHPURSPA-UHFFFAOYSA-N n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC(C)=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=N1 GHKQPVUHPURSPA-UHFFFAOYSA-N 0.000 claims 1
- IYCOPBHTSSZWLL-UHFFFAOYSA-N n-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NC(C)=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC=N1 IYCOPBHTSSZWLL-UHFFFAOYSA-N 0.000 claims 1
- NCYSURAZJLVZNC-UHFFFAOYSA-N n-[(2,5-dimethylpyrazol-3-yl)methyl]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound CN1N=C(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=N1 NCYSURAZJLVZNC-UHFFFAOYSA-N 0.000 claims 1
- ZWRMYOXRFVPNCH-UHFFFAOYSA-N n-[(2,5-dimethylpyrazol-3-yl)methyl]-2-methyl-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound CN1N=C(C)C=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=CC3=CC=2)=NC(C)=N1 ZWRMYOXRFVPNCH-UHFFFAOYSA-N 0.000 claims 1
- JZSSDQMNEYDQLS-UHFFFAOYSA-N n-[(2,5-dimethylpyrazol-3-yl)methyl]-2-methyl-6-[[2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound CN1N=C(C)C=C1CNC1=CC(OCC2C(C2)C=2N=CC(C)=CC=2)=NC(C)=N1 JZSSDQMNEYDQLS-UHFFFAOYSA-N 0.000 claims 1
- WFJXGHBYNAPPHB-UHFFFAOYSA-N n-[(2,5-dimethylpyrazol-3-yl)methyl]-6-[[2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy]-2-methylpyrimidin-4-amine Chemical compound N1=CC(OC)=CC=C1C1C(COC=2N=C(C)N=C(NCC=3N(N=C(C)C=3)C)C=2)C1 WFJXGHBYNAPPHB-UHFFFAOYSA-N 0.000 claims 1
- HUMOKQMMXAPEDG-UHFFFAOYSA-N n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound CC1=CN=C(F)C(CNC=2N=C(C)N=C(OCC3C(C3)C=3N=CC=CC=3)C=2)=C1 HUMOKQMMXAPEDG-UHFFFAOYSA-N 0.000 claims 1
- ORACWHWYLOTQCR-UHFFFAOYSA-N n-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]-2-methyl-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound C=1C(OCC2C(C2)C=2N=CC=CC=2)=NC(C)=NC=1NCC(S1)=NN=C1C1CC1 ORACWHWYLOTQCR-UHFFFAOYSA-N 0.000 claims 1
- QDXPZWAXPKHADU-UHFFFAOYSA-N n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]-2-(trifluoromethyl)pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC(C(F)(F)F)=N1 QDXPZWAXPKHADU-UHFFFAOYSA-N 0.000 claims 1
- MWGJZHYSZLTSCC-UHFFFAOYSA-N n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=CC=CC=2)=NC=N1 MWGJZHYSZLTSCC-UHFFFAOYSA-N 0.000 claims 1
- PFTCWFUNEJNIHY-UHFFFAOYSA-N n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=CC3=CC=2)=NC=N1 PFTCWFUNEJNIHY-UHFFFAOYSA-N 0.000 claims 1
- ZBROLCRTCOCWHV-UHFFFAOYSA-N n-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-[[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound S1C(C)=NN=C1CNC1=CC(OCC2C(C2)C=2N=C3C=CC=NC3=CC=2)=NC=N1 ZBROLCRTCOCWHV-UHFFFAOYSA-N 0.000 claims 1
- OPXAARKDQBLXMH-CVEARBPZSA-N n-[(5-tert-butyl-1,3,4-thiadiazol-2-yl)methyl]-2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1[C@@H]1[C@@H](COC=2N=C(C)N=C(NCC=3SC(=NN=3)C(C)(C)C)C=2)C1 OPXAARKDQBLXMH-CVEARBPZSA-N 0.000 claims 1
- QMTSFAXTEQKAIS-CABCVRRESA-N n-methoxy-n-methyl-5-[[[2-methyl-6-[[(1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-yl]amino]methyl]-1,3,4-thiadiazole-2-carboxamide Chemical compound S1C(C(=O)N(C)OC)=NN=C1CNC1=CC(OC[C@@H]2[C@H](C2)C=2N=CC(C)=CC=2)=NC(C)=N1 QMTSFAXTEQKAIS-CABCVRRESA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (29)
1. Spoj formule I:
[image]
u kojem:
A je izabran iz grupe koja se sastoji od:
(1) piridil,
(2) hinolinil,
(3) naftiridinil,
(4) tiazolil,
(5) piridazinil,
(6) oksazolil, i
(7) pirazolil,
(8) dihidropirolopirazolil,
(9) dihidrociklopentapiridinil,
(10) imidazopiridazinil, i
(11) pirazolopirimidinil;
B je izabran iz grupe koja se sastoji od:
(1) tiazolil,
(2) pirazolil,
(3) tiadiazolil,
(4) izoksazolil,
(5) izotiazolil,
(6) piridil, i
(7) pirimidinil;
R1a, R1b i R1c nezavisno su izabrani iz grupe koja se sastoji od:
(1) vodik,
(2) halogen,
(3) hidroksil,
(4) -(C=O)m-On-C1-6alkil, gdje m je 0 ili 1, n je 0 ili 1 (gdje ako je m jednako 0 ili n je 0, prisutna je veza) i gdje je alkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(5) -(C=O)m-On-C3-6cikloalkil, gdje je cikloalkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(6) -(C=O)m-C2-4alkenil, gdje je alkenil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(7) -(C=O)m-C2-4alkinil, gdje je alkinil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gdje je fenil ili naftil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(9) -(C=O)m-On-heteroaril, gdje je heteroaril nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(10) -(C=O)m-NR10R11,
(11) -S(O)2-NR10R11,
(12) -S(O)q-R12, gdje q je 0, 1 ili 2 i gdje R12 je izabran od definicija za R10 i R11,
(13) -CO2H,
(14) -CN, i
(15) -NO2;
R2a, R2b i R2c nezavisno su izabrani iz grupe koja se sastoji od:
(1) vodik,
(2) halogen,
(3) hidroksil,
(4) -(C=O)m-On-C1-6alkil, gdje je alkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(5) -(C=O)m-On-C3-6cikloalkil, gdje je cikloalkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(6) -(C=O)m-C2-4alkenil, gdje je alkenil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(7) -(C=O)m-C2-4alkinil, gdje je alkinil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gdje je fenil ili naftil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(9) -(C=O)m-On-heterociklil, gdje je heterociklil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R13,
(10) -(C=O)m-NR10R11,
(11) -S(O)2-NR10R11,
(12) -S(O)q-R12,
(13) -CO2H,
(14) -CN, i
(15) -NO2;
R3 je izabran iz grupe koja se sastoji od:
(1) CH3,
(2) CF3,
(3) CH2F,
(4) CH2CH3,
(5) ciklopropil,
(6) cijano,
(7) vodik,
(8) NH2,
(9) C(O)OR5,
(10) -O-C1-6alkil,
(11) -(CO)NH2,
(12) C1-6alkilOH,
(13) C(O) C1-6alkil, i
(14) halogen;
R4 je izabran iz grupe koja se sastoji od:
(1) vodik,
(2) halo,
(3) -C1-6alkil, i
(4) cijano,
R5 je izabran iz grupe koja se sastoji od:
(1) vodik, i
(2) C1-6alkil;
R6 je izabran iz grupe koja se sastoji od:
(1) vodik,
(2) C1-6alkil, i
(3) OC1-6alkil;
R10 i R11 nezavisno su izabrani iz grupe koja se sastoji od:
(a) vodik,
(b) C1-6alkil, koji je nesupstituiran ili supstituiran sa R14,
(c) C3-6alkenil, koji je nesupstituiran ili supstituiran sa R14,
(d) C3-6alkinil, koji je nesupstituiran ili supstituiran sa R14,
(e) C3-6cikloalkil koji je nesupstituiran ili supstituiran sa R14,
(f) C1-6alkoksil, koji je nesupstituiran ili supstituiran sa R14,
(g) fenil, koji je nesupstituiran ili supstituiran sa R14, i
(h) heteroaril, koji je nesupstituiran ili supstituiran sa R14,
R13 je izabran iz grupe koja se sastoji od:
(1) halogen,
(2) hidroksil,
(3) -(C=O)m-On-C1-6alkil, gdje je alkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(4) -On-(C1-3)perfluoroalkil,
(5) -(C=O)m-On-C3-6cikloalkil, gdje je cikloalkil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(6) -(C=O)m-C2-4alkenil, gdje je alkenil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(7) -(C=O)m-C2-4alkinil, gdje je alkinil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(8) -(C=O)m-On-fenil ili -(C=O)m-On-naftil, gdje je fenil ili naftil nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(9) -(C=O)m-On-heteroaril, gdje je heteroaril nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R14,
(10) -(C=O)m-NR10R11,
(11) -S(O)2-NR10R11,
(12) -S(O)q-R12,
(13) -CO2H,
(14) -CN, i
(15) -NO2;
R14 je izabran iz grupe koja se sastoji od:
(1) hidroksil,
(2) halogen,
(3) C1-6alkil,
(4) -C3-6cikloalkil,
(5) -O-C1-6alkil,
(6) -O(C=O)-C1-6alkil,
(7) -NH-C1-6alkil,
(8) fenil,
(9) heteroaril,
(10) -CO2H i
(11) -CN;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1 formule Ia:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je A izabran iz grupe koja se sastoji od:
(1) piridil,
(2) hinolinil i
(3) naftiridinil.
4. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je B izabran iz grupe koja se sastoji od:
(1) tiazolil,
(2) pirazolil i
(3) tiadiazolil.
5. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je B izabran iz grupe koja se sastoji od:
[image]
[image]
6. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje su R1a, R1b, R1c izabrani iz grupe koja se sastoji od:
(1) C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom ili hidroksil,
(2) -O-C1-6alkil, koji je nesupstituiran ili supstituiran sa halogenom ili hidroksil,
(3) fenil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil,
-NH2, -NH-C1-6alkil ili -N(C1-6alkil)(C1-6alkil), -O-C1-6alkil ili C1-6alkil, koji je nesupstituiran ili supstituiran sa fluoro,
(4) heteroaril, koji je nesupstituiran ili supstituiran sa halogen, hidroksil,
-NH2, -NH-C1-6alkil ili -N(C1-6alkil)(C1-6alkil), -O-C1-6alkil ili C1-6alkil, koji je nesupstituiran ili supstituiran sa fluoro,
(5) -O-fenil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil,
-NH2, -NH-C1-6alkil ili -N(C1-6alkil)(C1-6alkil), -O-C1-6alkil ili C1-6alkil, koji je nesupstituiran ili supstituiran sa fluoro, i
(6) -O-heteroaril, koji je nesupstituiran ili supstituiran sa halogen, hidroksil,
-NH2, -NH-C1-6alkil ili -N(C1-6alkil)(C1-6alkil), -O-C1-6alkil ili C1-6alkil, koji je nesupstituiran ili supstituiran sa fluoro.
7. Spoj prema patentnom zahtjevu 6, ili njegova farmaceutski prihvatljiva sol, u kojem R1a, R1b, R1c su izabrani iz grupe koja se sastoji:
(1) vodik,
(2) kloro,
(3) fluoro,
(4) bromo,
(5) metil,
(6) metoksi,
(7) (metil)ciklopropil-,
(8) ciklopropil,
(9) (metoksi)fenil- i
(10) (metil)fenil-.
8. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje su R2a, R2b i R2c nezavisno izabrani iz grupe koja se sastoji od:
(1) vodik,
(2) halogen,
(3) hidroksil,
(4) C1-6alkil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil ili fenil ili naftil,
(5) -O-C1-6alkil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil ili fenil,
(6) heterociklil, gdje je heterociklil izabran od imidazolil, izotiazolil, oksazolil, morfolinil, pirazolil, piridil, tetrazolil i tiazolil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil, C1-6alkil, -O-C1-6alkil ili -NO2, i
(7) fenil, koji je nesupstituiran ili supstituiran sa halogenom, hidroksil, C1-6alkil, -O-C1-6alkil ili -NO2.
9. Spoj prema patentnom zahtjevu 8, ili njegova farmaceutski prihvatljiva sol, gdje R2c je vodik i R2a i R2b nezavisno su izabrani iz grupe koja se sastoji od:
(1) vodik,
(2) kloro,
(3) fluoro,
(4) bromo,
(5) metil,
(6) ciklopropil;
(7) izopropoksi,
(8) metoksi i
(9) t-butoksi.
10. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje R3 je izabran iz grupe koja se sastoji od CH3, CF3 i CH2F.
11. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje R5 je izabran iz grupe koja se sastoji od vodika i metila.
12. Spoj prema patentnom zahtjevu 1 koji je izabran iz grupe koja se sastoji od:
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi] pirimidin-4-amin;
2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-6-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
N-[(1,3-dimetil-1H-pirazol-5-il)metil]-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metilpirimidin-4-amin;
S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metilpirimidin-4-amin;
N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-[(-2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-[(-2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
S,S-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-{[-2-(5-metilpiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-{[-2-(5-metilpiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
6-{[2-(3-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
6-{[2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
6-({2-[5-(fluorometil)piridin-2-il]ciklopropil}metoksi)-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
6-({2-[5-(difluorometil)piridin-2-il]ciklopropil}metoksi)-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4-amin;
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-({2-[5-(trifluorometil)piridin-2-il]ciklopropil}metoksi)pirimidin-4-amin;
2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-{[2-(1,3-tiazol-4-il)ciklopropil]metoksi}pirimidin-4-amin;
2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(2-metil-1,3-tiazol-5-il)metil]pirimidin-4-amin;
S,S-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(2-metil-1,3-tiazol-5-il)metil]pirimidin-4-amin;
6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]pirimidin-4-amin;
2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(2-metil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
6-{[2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-({2-[5-(fluorometil)piridin-2-il]ciklopropil}metoksi)-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-({2-[5-(difluorometil)piridin-2-il]ciklopropil}metoksi)-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin
2-metil-6-{[2-(6-metilpiridazin-3-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(2-metil-1,3-tiazol-4-il)ciklopropil]metoksi}pirimidin-4-amin;
2-metil-6-{[2-(2-metil-1,3-oksazol-4-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-6-{[2-(-metil-1H-pirazol-3-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
N-[(5-ciklopropil-1,3,4-tiadiazol-2-il)metil]-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(5-ciklopropil-1,3,4-tiadiazol-2-il)metil]-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol -5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
S,S-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-2,4-diamin;
S,S-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-2,4-diamin;
2-metoksi-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-metoksi-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2,5-dimetil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2,5-dimetil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2,5-dimetil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2,5-dimetil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-2-(trifluorometil)pirimidin-4-amin;
S,S-N-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-2-(trifluorometil)pirimidin-4-amin;
6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-2-(trifluorometil)pirimidin-4-amin;
S,S-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-2-(trifluorometil)pirimidin-4-amin;
N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]-2-(trifluorometil)pirimidin-4-amin;
S,S-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]-2-(trifluorometil)pirimidin-4-amin;
N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]-2-(trifluorometil)pirimidin-4-amin;
S,S-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]-2-(trifluorometil)pirimidin-4-amin;
6-{[2-(5,6-dihidro-4H-pirolo[1,2-b]pirazol-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-{[(1S,2S)-2-(5,6-dihidro-4H-pirolo[1,2-b]pirazol-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
S,S-6-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-pirazolo[1,5-a]pirimidin-2-ilciklopropil]metoksi}pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[(1S,2S)-2-pirazolo[1,5-a]pirimidin-2-ilciklopropil]metoksi}pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-pirazolo[1,5-a]pirimidin-5-ilciklopropil]metoksi}pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(1S,2S)-2-pirazolo[1,5-a]pirimidin-5-ilciklopropil]metoksi}pirimidin-4-amin;
6-{[2-(5-bromopiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-6-{[(1S,2S)-2-(5-bromopiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-6-{[2-(2-metilimidazo[1,2-b]piridazin-6-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-6-{[(1S,2S)-2-(2-metilimidazo[1,2-b]piridazin-6-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
5-kloro-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-5-kloro-2-metil-6-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-etil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-5-fluoro-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-5-fluoro-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-5-fluoro-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-5-fluoro-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
5-fluoro-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(-2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-5-fluoro-2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(-2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
5-fluoro-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
S,S-5-fluoro-2-metil-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-(fluorometil)-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-(fluorometil)-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2-etil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-2-etil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-etil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-etil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
-ciklopropil-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-ciklopropil-N-[(2,4-dimetil-1,3-tiazol-5-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-ciklopropil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-2-ciklopropil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
5-fluoro-6-{[2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-6-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[(1S,2S)-2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-2,4-diamin;
5-fluoro-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-6-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[(1S,2S)-2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[(1S,2S)-2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
N-4-(2,4-dimetoksibenzil)-5-fluoro-6-{[2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
N-4-(2,4-dimetoksibenzil)-5-fluoro-6-{[(1S,2S)-2-piridin-2-ilciklopropil]metoksi}pirimidin-2,4-diamin;
6-{[2-(5-kloropiridin-2-il)ciklopropil]metoksi}-5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
6-{[(1S,2S)-2-(5-kloropiridin-2-il)ciklopropil]metoksi}-5-fluoro-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-6-{[2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-fluoro-6-{[(1S,2S)-2-(5-fluoropiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-kloro-6-{[2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
5-kloro-6-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
6-{[2-(4,5-dimetilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
6-{[(1S,2S)-2-(4,5-dimetilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin;
6-((2-(5,6-dihidro-4H-pirolo[1,2-b]pirazol-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-(((1S,2S)-2-(5,6-dihidro-4H-pirolo[1,2-b]pirazol-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-((2-(6-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2,4-diamin;
5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-(((1S,2S)-2-(6-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
6-((2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
S,S-6-(((1S,2S)-2-(6,7-dihidro-5H-ciklopenta[b]piridin-2-il)ciklopropil)metoksi)-5-fluoro-N4-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-2,4-diamin;
5-bromo-N-((2,4-dimetiltiazol-5-il)metil)-2-metil-6-((2-(piridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
4-((2,4-dimetiltiazol-5-il)metilamino)-2-metil-6-((2-(piridin-2-il)ciklopropil)metoksi)pirimidin-5-karbonitril;
2-metil-4-((1-metil-1H-pirazol-4-il)metilamino)-6-((2-(piridin-2-il)ciklopropil)metoksi)pirimidin-5-karbonitril;
4-((1-metil-1H-pirazol-4-il)metilamino)-6-((2-(piridin-2-il)ciklopropil)metoksi)-pirimidin-2-karboksamid;
4-((1-metil-1H-pirazol-4-il)metilamino)-6-((2-(piridin-2-il)ciklopropil)metoksi)-pirimidin-2-karbonitril;
2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-((2-(5-(tiazol-4-il)piridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
6-{[2-(2,3'-bipiridin-6'-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-({2-[5-(1,3-tiazol-5-il)piridin-2-il]ciklopropil}metoksi)pirimidin-4-amin;
6-{[2-(3,4'-bipiridin-6-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-({2-[5-(1,3-tiazol-2-il)piridin-2-il]ciklopropil}metoksi)pirimidin-4-amin;
6-{[2-(3,3'-bipiridin-6-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(5-piridazin-4-ilpiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin;
6-((2-(5-etilpiridin-2-il)ciklopropil)metoksi)-2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-4-amin;
6-{[2-(5-ciklopropilpiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin;
6-((2-(5-(1H-pirazol-1-il)piridin-2-il)ciklopropil)metoksi)-2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-4-amin;
6-(2-((2-metil-6-((5-metil-1,3,4-tiadiazol-2-il)metilamino)pirimidin-4-iloksi)metil)ciklopropil)nikotinonitril;
2-metil-N-((5-metilisoksazol-3-il)metil)-6-((2-(piridin-2-il)ciklopropil)metoksi)-pirimidin-4-amin;
N-[(2-fluoro-5-metilpiridin-3-il)metil]-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
S,S-N-(izotiazol -5-ilmetil)-2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-N-[(5-metilpirazin-2-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin;
2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]-N-(pirimidin-5-ilmetil)pirimidin-4-amin;
2-metil-6-((2-(piridin-2-il)ciklopropil)metoksi)-N-(piridin-4-ilmetil)pirimidin-4-amin;
2-metil-6-[(2-piridin-2-ilciklopropil)metoksi]-N-(piridin-3-ilmetil)pirimidin-4-amin;
2-metil-N-((3-metilpiridin-4-il)metil)-6-((2-(piridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
6-(2-((2-metil-6-((5-metil-1,3,4-tiadiazol-2-il)metilamino)pirimidin-4-iloksi)metil)ciklopropil)piridine;
2-amino-4-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril;
2-amino-4-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril; i
S,S-2-amino-4-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril; i
2-amino-4-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril;
S,S-2-amino-4-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril;
N-metoksi-N-metil-5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-karboksamid;
1-(5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-il)etanon;
1-(5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-il)etanol;
4-((5-metil-1,3,4-tiadiazol-2-il)metilamino)-6-(((1R,2R)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2-karboksilna kiselina;
etil 4-((5-metil-1,3,4-tiadiazol-2-il)metilamino)-6-(((1R,2R)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2-karboksilat;
2-(5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-il)propan-2-ol;
2-(6-((1S,2S)-2-((2-metil-6-((5-metil-1,3,4-tiadiazol-2-il)metilamino)pirimidin-4-iloksi)metil)ciklopropil)piridin-3-il)propan-2-ol;
metil 5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-karboksilat;
5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-karbonitril;
5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-karboksamid;
6-(((1S,3S)-2-terc-butoksi-3-(5-metilpiridin-2-il)ciklopropil)metoksi)-2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)pirimidin-4-amin;
2-etil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
2-(4-((5-metil-1,3,4-tiadiazol-2-il)metilamino)-6-(((1R,2R)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2-il)propan-2-ol;
N-((5-terc-butil-1,3,4-tiadiazol-2-il)metil)-2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
1-(4-((5-metil-1,3,4-tiadiazol-2-il)metilamino)-6-(((1R,2R)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-2-il)etanon;
2-metil-N-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-(((1R,2R)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
1-(5-((2-metil-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-ilamino)metil)-1,3,4-tiadiazol-2-il)etanol;
2-kloro-N-((5-metil-1,3,4-tiadiazol-2-il)metil)-6-(((1S,2S)-2-(5-metilpiridin-2-il)ciklopropil)metoksi)pirimidin-4-amin;
ili njegova farmaceutski prihvatljiva sol.
13. Spoj prema patentnom zahtjevu 12 koji je 2-metil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
14. Spoj prema patentnom zahtjevu 12 koji je 2-metil-6-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
15. Spoj prema patentnom zahtjevu 12 koji je S,S-N-[(1,3-dimetil-1H-pirazol-5-il)metil]-2-metil-6-[(2-hinolin-2-ilciklopropil)metoksi]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
16. Spoj prema patentnom zahtjevu 12 koji je S,S-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]-6-{[2-(1,5-naftiridin-2-il)ciklopropil]metoksi}pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
17. Spoj prema patentnom zahtjevu 12 koji je S,S-6-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin ili njegova farmaceutski prihvatljiva sol.
18. Spoj prema patentnom zahtjevu 12 koji je 2-etil-N-[(1-metil-1H-pirazol-4-il)metil]-6-[(2-piridin-2-ilciklopropil)metoksi]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
19. Spoj prema patentnom zahtjevu 12 koji je 5-fluoro-6-{[(1S,2S)-2-(5-metoksipiridin-2-il)ciklopropil]metoksi}-N-4-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-2,4-diamin ili njegova farmaceutski prihvatljiva sol
20. Spoj prema patentnom zahtjevu 12 koji je 6-{[2-(3,3'-bipiridin-6-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
21. Spoj prema patentnom zahtjevu 12 koji je 6-{[2-(5-ciklopropilpiridin-2-il)ciklopropil]metoksi}-2-metil-N-[(5-metil-1,3,4-tiadiazol-2-il)metil]pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
22. Spoj prema patentnom zahtjevu 12 koji je 2-metil-N-((5-metilisoksazol-3-il)metil)-6-((2-(piridin-2-il)ciklopropil)metoksi)-pirimidin-4-amin ili njegova farmaceutski prihvatljiva sol.
23. Spoj prema patentnom zahtjevu 12 koji je 2-amino-4-{[(1S,2S)-2-(5-metilpiridin-2-il)ciklopropil]metoksi}-6-{[(5-metil-1,3,4-tiadiazol-2-il)metil]amino}pirimidin-5-karbonitril ili njegova farmaceutski prihvatljiva sol.
24. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv nosač i spoj prema bilo kojem prethodnom patentnom zahtjevu ili njegovu farmaceutski prihvatljivu sol.
25. Spoj prema bilo kojem od patentnih zahtjeva 1-23 ili njegova farmaceutski prihvatljiva sol za uporabu u medicini.
26. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-23 ili njegove farmaceutski prihvatljive soli, za proizvodnju lijeka za liječenje poremećaja izabranog od psihotičnih poremećaja, deluzionih poremećaja i psihoze inducirane lijekom; anksioznih poremećaja, poremećaja kretanja, poremećaja raspoloženja i neurodegenerativnih poremećaja.
27. Spoj prema bilo kojem od patentnih zahtjeva 1-23 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju neurološkog ili psihijatrijskog poremećaja povezanog sa disfunkcijom PDE10 kod pacijenta sisara kod kojeg postoji potreba za tim.
28. Spoj prema bilo kojem od patentnih zahtjeva 1-23 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju neurološkog ili psihijatrijskog poremećaja povezanog sa striatalnom hipofunkcijom ili disfunkcijom bazalne ganglije kod pacijenta sisara kod kojeg postoji potreba za tim.
29. Spoj prema bilo kojem od patentnih zahtjeva 1-23 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju šizofrenije kod pacijenta sisara kod kojeg postoji potreba za tim.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161527392P | 2011-08-25 | 2011-08-25 | |
PCT/US2012/051522 WO2013028590A1 (en) | 2011-08-25 | 2012-08-20 | Pyrimidine pde10 inhibitors |
EP12826375.3A EP2748151B1 (en) | 2011-08-25 | 2012-08-20 | Pyrimidine pde10 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160635T1 true HRP20160635T1 (hr) | 2016-07-01 |
Family
ID=47746797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160635TT HRP20160635T1 (hr) | 2011-08-25 | 2016-06-08 | Inhibitori pirimidina pde10 |
Country Status (36)
Country | Link |
---|---|
US (1) | US9062059B2 (hr) |
EP (1) | EP2748151B1 (hr) |
JP (1) | JP5648147B2 (hr) |
KR (1) | KR101655635B1 (hr) |
CN (1) | CN103917528B (hr) |
AR (1) | AR087628A1 (hr) |
AU (1) | AU2012299080B2 (hr) |
BR (1) | BR112014004310B8 (hr) |
CA (1) | CA2845578C (hr) |
CL (1) | CL2014000450A1 (hr) |
CO (1) | CO6890101A2 (hr) |
CR (1) | CR20140085A (hr) |
CY (1) | CY1117622T1 (hr) |
DK (1) | DK2748151T3 (hr) |
DO (1) | DOP2014000039A (hr) |
EA (1) | EA023685B1 (hr) |
ES (1) | ES2572527T3 (hr) |
HK (1) | HK1193410A1 (hr) |
HR (1) | HRP20160635T1 (hr) |
HU (1) | HUE028451T2 (hr) |
IL (1) | IL230997A (hr) |
MA (1) | MA35508B1 (hr) |
ME (1) | ME02419B (hr) |
MX (1) | MX357241B (hr) |
MY (1) | MY157301A (hr) |
NI (1) | NI201400014A (hr) |
PE (1) | PE20141535A1 (hr) |
PL (1) | PL2748151T3 (hr) |
RS (1) | RS54788B1 (hr) |
SG (1) | SG2014013536A (hr) |
SI (1) | SI2748151T1 (hr) |
TN (1) | TN2014000070A1 (hr) |
TW (1) | TWI450895B (hr) |
UA (1) | UA109735C2 (hr) |
WO (1) | WO2013028590A1 (hr) |
ZA (1) | ZA201401272B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013052526A1 (en) | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
EP2763672B1 (en) | 2011-10-06 | 2016-08-10 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
WO2014078217A1 (en) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine pde10 inhibitors |
TW201422610A (zh) * | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲pde10抑制劑之經二級醇取代之三唑 |
US9284302B2 (en) | 2012-11-15 | 2016-03-15 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as PDE 10 inhibitors |
WO2014081619A1 (en) * | 2012-11-20 | 2014-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
WO2014139150A1 (en) | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
LT3122745T (lt) | 2014-03-24 | 2019-04-10 | Novartis Ag | Monobaktamo organiniai junginiai, skirti bakterinių infekcijų gydymui |
US10125101B2 (en) | 2016-11-28 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
AR125085A1 (es) | 2021-03-17 | 2023-06-07 | Merck Sharp & Dohme Llc | Profármacos de compuestos de pde10 |
WO2023184486A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol |
CN115403527B (zh) * | 2022-07-20 | 2024-03-29 | 西安近代化学研究所 | 一种还原胺化法合成杀菌剂乙嘧酚的方法 |
WO2024049721A1 (en) * | 2022-08-31 | 2024-03-07 | Merck Sharp & Dohme Llc | Sustained release delivery of a pde10 inhibitor |
WO2024099135A1 (zh) * | 2022-11-11 | 2024-05-16 | 杭州中美华东制药有限公司 | 1,5-萘啶类cGAS抑制剂及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
WO2006044372A2 (en) | 2004-10-12 | 2006-04-27 | Maxlinear, Inc. | A receiver architecture with digitally generated intermediate frequency |
RS51385B (en) | 2005-01-07 | 2011-02-28 | Pfizer Products Inc. | HETEROAROMATIC COMPOUNDS OF HINOLINE AND THEIR USE AS PDE10 INHIBITORS |
GB0506883D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
CA2602372A1 (en) * | 2005-04-05 | 2006-10-12 | Astrazeneca Ab | Pyrimidine derivatives for use as anticancer agents |
NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
CA2650976A1 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
KR101324329B1 (ko) | 2008-09-04 | 2013-10-31 | 미쓰비시 타나베 파마 코퍼레이션 | 삼치환된 피리미딘 화합물 및 pde10 억제제로서의 그의 용도 |
ES2412780T3 (es) | 2008-09-10 | 2013-07-12 | Mitsubishi Tanabe Pharma Corporation | Compuestos aromáticos de anillo de 6 miembros que contiene nitrógeno y su uso |
AR074343A1 (es) * | 2008-11-14 | 2011-01-12 | Amgen Inc | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 |
ES2397934T3 (es) * | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
US8957077B2 (en) * | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
-
2012
- 2012-08-20 AU AU2012299080A patent/AU2012299080B2/en active Active
- 2012-08-20 PE PE2014000255A patent/PE20141535A1/es active IP Right Grant
- 2012-08-20 ME MEP-2016-101A patent/ME02419B/me unknown
- 2012-08-20 ES ES12826375.3T patent/ES2572527T3/es active Active
- 2012-08-20 EP EP12826375.3A patent/EP2748151B1/en active Active
- 2012-08-20 BR BR112014004310A patent/BR112014004310B8/pt active IP Right Grant
- 2012-08-20 TW TW101130166A patent/TWI450895B/zh active
- 2012-08-20 SG SG2014013536A patent/SG2014013536A/en unknown
- 2012-08-20 SI SI201230539A patent/SI2748151T1/sl unknown
- 2012-08-20 MX MX2014002178A patent/MX357241B/es active IP Right Grant
- 2012-08-20 HU HUE12826375A patent/HUE028451T2/en unknown
- 2012-08-20 MY MYPI2014000504A patent/MY157301A/en unknown
- 2012-08-20 KR KR1020147007427A patent/KR101655635B1/ko active IP Right Grant
- 2012-08-20 WO PCT/US2012/051522 patent/WO2013028590A1/en active Application Filing
- 2012-08-20 CA CA2845578A patent/CA2845578C/en active Active
- 2012-08-20 RS RS20160357A patent/RS54788B1/sr unknown
- 2012-08-20 DK DK12826375.3T patent/DK2748151T3/en active
- 2012-08-20 UA UAA201403008A patent/UA109735C2/ru unknown
- 2012-08-20 EA EA201490492A patent/EA023685B1/ru not_active IP Right Cessation
- 2012-08-20 US US14/239,603 patent/US9062059B2/en active Active
- 2012-08-20 PL PL12826375.3T patent/PL2748151T3/pl unknown
- 2012-08-20 CN CN201280052330.4A patent/CN103917528B/zh active Active
- 2012-08-20 JP JP2014527214A patent/JP5648147B2/ja active Active
- 2012-08-22 AR ARP120103086A patent/AR087628A1/es active IP Right Grant
-
2014
- 2014-02-16 IL IL230997A patent/IL230997A/en active IP Right Grant
- 2014-02-18 TN TNP2014000070A patent/TN2014000070A1/en unknown
- 2014-02-19 ZA ZA2014/01272A patent/ZA201401272B/en unknown
- 2014-02-24 NI NI201400014A patent/NI201400014A/es unknown
- 2014-02-24 CR CR20140085A patent/CR20140085A/es unknown
- 2014-02-25 DO DO2014000039A patent/DOP2014000039A/es unknown
- 2014-02-25 CL CL2014000450A patent/CL2014000450A1/es unknown
- 2014-02-27 CO CO14042266A patent/CO6890101A2/es unknown
- 2014-03-13 MA MA6829A patent/MA35508B1/fr unknown
- 2014-07-07 HK HK14106824.3A patent/HK1193410A1/zh unknown
-
2016
- 2016-06-08 HR HRP20160635TT patent/HRP20160635T1/hr unknown
- 2016-06-10 CY CY20161100512T patent/CY1117622T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160635T1 (hr) | Inhibitori pirimidina pde10 | |
HRP20171913T1 (hr) | Aminopirimidinilni spojevi kao inhibitori jak | |
HRP20200962T1 (hr) | Novi spojevi | |
US7880000B2 (en) | Protein kinase modulators and method of use | |
HRP20160574T1 (hr) | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida | |
JP2010512337A5 (hr) | ||
IL273705B2 (en) | Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases | |
RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
JP2013508405A5 (hr) | ||
HRP20110158T1 (hr) | Biaril eterski spojevi ureje | |
JP2009531309A5 (hr) | ||
JP2017530960A5 (hr) | ||
HRP20150347T1 (hr) | Analozi 2-aminopiridina kao aktivatori glukokinaze | |
HRP20100603T1 (hr) | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze | |
JP2019535728A (ja) | キナーゼ阻害剤としての複素環式アミド | |
JP2011506417A5 (hr) | ||
HRP20120251T1 (hr) | Derivati benzotiazol ciklobutil amina i njihova uporaba kao liganda receptora histamin | |
JP2016507551A5 (hr) | ||
RU2012105284A (ru) | Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания | |
RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
JP2018508553A5 (hr) | ||
JP2016514717A5 (hr) | ||
JP2018537408A5 (hr) | ||
MY162461A (en) | Substituted benzamide derivatives |